NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
Back to search
Official data from USPTO
POLYPEPTIDE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079378525Class
1, 3, 5, 35, 40, 42
Filing
79378525
Registration
7616806
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/03/2026
Trademark type
Combined
Nice classes
1, 3, 5, 35, 40, 42
Filing date
05/05/2023
Registration date
12/24/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
16
Owner location
SE
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a stylized atomic model in green. To the right of this design is the wording "POLYPEPTIDE" in black font. The white in the mark is background only and is not claimed as a feature of the mark.
Holders and representatives
Holders
Polypeptide Laboratories Holding (PPL) AB
Representatives
Bethany J. Whelan Dority & Manning, P.A.
Technical classification
Nice Classes
Class 1Class 3Class 5Class 35Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
Class 3
Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
Class 5
Synthetic peptides for pharmaceutical purposesfor use in oncologymetabolic disordersneurologygastrointestinal diseasescardiovascularreproductive healthimmune systemnutritional disorders hormonal disordersmusculoskeletal disordersanestheticscnsimmunology for the treatment of obesitydiabetescancerendometriosisup-regulation of growth hormonelipodystrophy in hiv/aidssleeping disordersendometriosisautoimmune diseasesesophageal hemorrhagehypercalcemiadental infiltrationirritable bowel syndromehypotensionachondroplasiamultiple myelomanon-metastatic osteosarcomaerectile dysfunctiondelaying imminent pre-term birthpostpartum hemorrhagespinocerebellar degenerationhypoactive sexual desire disorderosteoporosispost-menopausal osteoporosischronic idiopathic constipationacute decompensated heart failuresepsis and septic shockacute attacks of hereditary angioedemagastrointestinal bleedingtreatment of hiv-1reduction of hiv lipodystrophysevere chronic painchronic immune thrombocytopenic purpuratreatment of anemia associated with kidney diseaseprevention of respiratory distress syndromeprevention of phototoxicitymyocardial infarctiontreatment of refractory hypotension in adults with septic or other distributive shockirritable bowel syndromemyasthenia gravisuremic pruritusrenal puritushepatorenal syndromegrowth hormone related diseasesacromegalyesophageal varicesbed wettingpolyuriahyperuresishemophilia apremature labortocolysisautoimmune diseasesinfantile spasmsrheumatoid arthritismultiple sclerocsishepatitis btreatment of chushing's diseasetreatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumorsdiagnose of somatostatin receptor-positive neuroendocrine tumorsbacterial infectionsviral infectionsfungal infectionscardiovascular diseasesendocrine disordersneurological conditionsallergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncologyneurologyrare diseases for the treatment of genetic disordersneurodegenerative diseases and cancer; pharmaceutical and veterinary preparationssynthetic peptides for pharmaceutical and veterinary purposes for fertility control in animalsinduction of ovulation in marescastration of dogsfacilitation of parturition in livestock; biological preparations for medical and veterinary purposespolypetide biochemicals for medical and veterinary purposes for oncologymetabolic disordersneurologygastrointestinal diseasescardiovascularreproductive healthimmune systemnutritional disorders hormonal disordersmusculoskeletal disordersanestheticscnsimmunology for the treatment of obesitydiabetescancerendometriosisup-regulation of growth hormonelipodystrophy in hiv/aidssleeping disordersendometriosisautoimmune diseasesesophageal hemorrhagehypercalcemiadental infiltrationirritable bowel syndromehypotensionachondroplasiamultiple myelomanon-metastatic osteosarcomaerectile dysfunctiondelaying imminent pre-term birthpostpartum hemorrhagespinocerebellar degenerationhypoactive sexual desire disorderosteoporosispost-menopausal osteoporosischronic idiopathic constipationacute decompensated heart failuresepsis and septic shockacute attacks of hereditary angioedemagastrointestinal bleedingtreatment of hiv-1reduction of hiv lipodystrophysevere chronic painchronic immune thrombocytopenic purpuratreatment of anemia associated with kidney diseaseprevention of respiratory distress syndromeprevention of phototoxicitymyocardial infarctiontreatment of refractory hypotension in adults with septic or other distributive shockirritable bowel syndromemyasthenia gravisuremic pruritusrenal puritushepatorenal syndromegrowth hormone related diseasesacromegalyesophageal varicesbed wettingpolyuriahyperuresishemophilia apremature labortocolysisautoimmune diseasesinfantile spasmsrheumatoid arthritismultiple sclerocsishepatitis btreatment of chushing's diseasetreatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumorsdiagnose of somatostatin receptor-positive neuroendocrine tumorsbacterial infectionsviral infectionsfungal infectionscardiovascular diseasesendocrine disordersneurological conditionsallergic reactions plant; medicated dandruff and hair loss shampoosmedicated hair lotions for treating dandruff hair loss and hair damagemedicated soap cleansers for the skinmedicated cosmeticsnamely creams for treating acneirritateditchinginflamed skinrepairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressingsmedical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
Class 35
Advertising services; business administration; business management; providing office function
Class 40
Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing
Class 42
Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/22/2024
PUBO
PUBLISHED FOR OPPOSITION
10/22/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/16/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
09/16/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/16/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
09/16/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/16/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/28/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/28/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/28/2024
RFNT
REFUSAL PROCESSED BY IB
03/19/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/28/2024
RFRR
REFUSAL PROCESSED BY MPU
02/28/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/07/2024
CNRT
NON-FINAL ACTION WRITTEN
02/06/2024
DOCK
ASSIGNED TO EXAMINER
01/31/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/22/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/18/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/14/2023
Continuous trademark protection
Get notified about every new filing that threatens POLYPEPTIDE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.